Список литературы

56. Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31. DOI:10.4161/ORG.7.1.14027.

57. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):81. DOI:10.1056/NEJM199108083250604.

58. Henon P. Thrombotic thrombocytopenic purpura: Clinical results of a French controlled trial. Transfus Sci. 1992;13(1):63–72. DOI:10.1016/0955-3886(92)90123-X.

59. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320–8. DOI:10.1046/J.1526-0968.2002.00390.X.

60. Rock G., Shumak K.H., Sutton D.M., et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol. 1996;94(2):383–6. DOI:10.1046/J.1365-2141.1996.D01-1800.X.

61. Mazepa M.A., Raval J.S., Brecher M.E., et al. Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise. J Clin Apher. 2018;33(3):291–6. DOI:10.1002/JCA.21600.

62. Altuntas F., Aydogdu I., Kabukcu S., et al. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2007;36(1):57–67. DOI:10.1016/J.TRANSCI.2006.05.014.

63. Zeigler Z.R., Shadduck R.K., Gryn J.F., et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher. 2001;16(1):19–22. DOI:10.1002/JCA.1003.

64. Lin Q., Fan L., Huang H., et al. Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Biomed Res Int. 2019;2019. DOI:10.1155/2019/1756109.

65. Moake J.L., Byrnes J.J., Troll J.H., et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1985;65(5):1232–6.

66. Stefanello B., De Paula E.V., Andrade Orsi F., et al. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation. J Clin Apher. 2014;29(6):311–5. DOI:10.1002/JCA.21336.

67. Raife T.J., Friedman K.D., Dwyre D.M. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Transfusion. 2006;46(1):74–9. DOI:10.1111/J.1537-2995.2005.00674.X.

68. Rock G., Ahluwalia N., Anderson D. Metalloprotease levels are variably altered in thrombotic thrombocytopenic patients at presentation and after plasma exchange with either cryosupernatant plasma or fresh frozen plasma. Blood. 2001;102:539a.

69. Thejeel B., Garg A.X., Clark W.F., et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol. 2016;91(6):623–30. DOI:10.1002/AJH.24339.

70. Sayani F.A., Abrams C.S. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860–7. DOI:10.1182/BLOOD-2014-11-551580.

71. Bell W.R., Braine H.G., Ness P.M., et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403. DOI:10.1056/NEJM199108083250605.

72. Toyoshige M., Zaitsu Y., Okafuji K., et al. Successful treatment of thrombotic thrombocytopenic purpura with high‐dose corticosteroid. Vol. 41, Am J Hematol. Am J Hematol; 1992. p. 69. DOI:10.1002/ajh.2830410119.

73. Balduini C.L., Gugliotta L., Luppi M., et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591–6. DOI:10.1007/S00277-009-0877-5.

74. Rojnuckarin P., Watanaboonyongcharoen P., Akkawat B., et al. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(5):1148–50. DOI:10.1111/J.1538-7836.2006.01879.X.

75. George J.N., Woodson R.D., Kiss J.E., et al. Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders. J Clin Apher. 2006;21:49–56. DOI:10.1002/jca.20091.

76. Regazzi M.B., Iacona I., Avanzini M.A., et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785–92. DOI:10.1097/01.FTD.0000184162.60197.C1.

77. Tobinai K., Igarashi T., Itoh K., et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2004;15(5):821–30. DOI:10.1093/ANNONC/MDH176.

78. Chen H., Fu A., Wang J., et al. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253–60. DOI:10.1177/0300060517695646.

79. McDonald V., Manns K., Mackie I.J., et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. DOI:10.1111/J.1538-7836.2010.03818.X.

80. Westwood J.P., Thomas M., Alwan F., et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–66. DOI:10.1182/BLOODADVANCES.2017008268.

81. Scully M., McDonald V., Cavenagh J., et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53. DOI:10.1182/BLOOD-2011-03-341131.

82. Chemnitz J., Draube A., Scheid C., et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71(2):105–8. DOI:10.1002/AJH.10204.

83. Froissart A., Buffet M., Veyradier A., et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104–11. DOI:10.1097/CCM.0B013E31822E9D66.

84. Scully M., Cohen H., Cavenagh J., et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. DOI:10.1111/J.1365-2141.2006.06448.X.

85. Jestin M., Center on behalf of the F.T.M.R., Benhamou Y., et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132(20):2143–53. DOI:10.1182/BLOOD-2018-04-840090.

86. Upreti H., Kasmani J., Dane K., et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037–45. DOI:10.1182/BLOOD.2019001056.

87. Scully M., Thomas M., Underwood M., et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211–9. DOI:10.1182/BLOOD-2014-02-553131.

88. Cataland S.R., Jin M., Lin S., et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol. 2007;139(3):486–93. DOI:10.1111/J.1365-2141.2007.06819.X.

89. Patriquin C.J., Thomas M.R., Dutt T., et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016;173(5):779–85. DOI:10.1111/BJH.13993.

90. Maschan A., Petrova U., Kalinina I., et al. Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases. Pediatr blood & cancer. 2021;68(4):e28818. DOI:10.1002/PBC.28818.

91. Pasquale D., Vidhya R., Dasilva K., et al. Chronic Relapsing Thrombotic Thrombocytopenic Purpura: Role of Therapy With Cyclosporine. J Hematol. 1998;57:57–61. DOI:10.1002/(SICI)1096-8652(199801)57:1.

92. Subklewe M., Sebelin-Wulf K., Beier C., et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol. 2007;68(3):147–55. DOI:10.1016/J.HUMIMM.2006.12.005.

93. Kappers-Klunne M.C., Wijermans P., Fijnheer R., et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130(5):768–76. DOI:10.1111/J.1365-2141.2005.05681.X.

94. Dubois L., Gray D.K. Splenectomy: Does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg. 2010;53(5):349.

95. Rutkow I.M. Thrombotic thrombocytopenic purpura (TTP) and splenectomy: a current appraisal. Ann Surg. 1978;188(5):701–5. DOI:10.1097/00000658-197811000-00021.

96. Veltman G.A.M., Brand A., Leeksma O.C., et al. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol. 1995;70(5):231–6. DOI:10.1007/BF01784041.

97. Аксельрод Б.А., Балашова Е.Н., Баутин А.Е., et al. Клиническое использование эритроцитсодержащих компонентов донорской крови. Гематология и трансфузиология. 2018;63(4):372–435. DOI:10.25837/HAT.2019.62.39.006.

98. Benhamou Y., Baudel J.L., Wynckel A., et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Am J Hematol. 2015;90(6):E127–9. DOI:10.1002/AJH.23997.

99. Bobbio-Pallavicini E., Gugliotta L., Centurioni R., et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997;82(4):429–35.

100. Момот А.П., Молчанова И.В., Батрак Т.А. Референтные значения показателей системы гемостаза при физиологически протекающей беременности и после родоразрешения. Проблемы репродукции. 2015;21(1):89–97. DOI:10.17116/repro20152189-97.

101. Sánchez-Luceros A., Farías C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost. 2004;92(6):1320–6. DOI:10.1160/TH03-11-0683.

102. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730–5. DOI:10.1182/BLOOD.V98.9.2730.

103. Roose E., Tersteeg C., Demeersseman R., et al. Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of Pregnancy-Onset Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open Companion J to Thromb Haemost. 2018;2(1):e8. DOI:10.1055/S-0037-1615252.

104. Ferrari B., Maino A., Lotta L.A., et al. Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. Orph J Rare Dis. 2014;9:193. DOI:10.1186/s13023-014-0193-6.

105. Jiang Y., McIntosh J.J., Reese J.A., et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123(11):1674–80. DOI:10.1182/BLOOD-2013-11-538900.

106. Gupta M., Feinberg B.B., Burwick R.M. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens. 2018;12:29–34. DOI:10.1016/J.PREGHY.2018.02.007.